At Samsung Bioepis, we deeply understand the urgent need for new treatment options for patients facing serious or life-threatening conditions. We appreciate the interest in our investigational medicines, and our team is working diligently to develop them as safely and efficiently as possible.
To deliver our investigational therapies to the greatest number of patients, Samsung Bioepis does not currently offer an expanded access program. We believe that dedicating our resources to conducting well-controlled clinical trials is the most efficient and responsible path to demonstrate clinical safety and efficacy, obtain regulatory approvals, and ultimately ensure broad, equitable access.
Our team will acknowledge receipt of inquiries sent to epis.EAP@samsung.com within 5 business days.
Information about Samsung Bioepis's open clinical trials is available on ClinicalTrials.gov.
*In line with the 21st Century Cures Act, Samsung Bioepis may revise this policy at any time.